Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
Zachariah DeFilippPatricia Pringle BloomMariam Torres SotoMichael K MansourMohamad R A SaterMiriam H HuntleySarah TurbettRaymond T ChungYi-Bin ChenElizabeth L HohmannPublished in: The New England journal of medicine (2019)
Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent or refractory Clostridioides difficile infection and is being actively investigated for other conditions. We describe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.
Keyphrases
- escherichia coli
- drug resistant
- end stage renal disease
- clinical trial
- newly diagnosed
- multidrug resistant
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- klebsiella pneumoniae
- prognostic factors
- randomized controlled trial
- stem cells
- acinetobacter baumannii
- emergency department
- gene expression
- dna methylation
- bone marrow
- risk assessment
- pseudomonas aeruginosa
- high resolution
- genome wide
- copy number
- cell therapy
- climate change